A Study of LY3090106 in Japanese and Caucasian Healthy Participants

Inclusion Criteria: * Overtly healthy Japanese or Caucasian * Body mass index (BMI) 18.0 - 32.0 kilograms per square meter (kg/m²) Exclusion Criteria: * Have participated, within the last 30 days, in a clinical study involving an investigational product (IP). If the previous IP has a long half-life, 5 half-lives or 30 days (whichever is longer) should have passed * Have had symptomatic herpes zoster within 3 months of screening * Show evidence of active or latent tuberculosis (TB) * Have known hypogammaglobulinemia or a screening serum immunoglobulin (Ig) G \<565 milligrams per deciliter (mg/dL) * Have received live or attenuated vaccine(s) within 1 month of screening, or intend to during the study * Are immunocompromised * Have received treatment with biologic agents (such as monoclonal antibodies, including marketed drugs) within 3 months or 5 half-lives (whichever is longer) prior to dosing. Participants with any prior exposure to ixekizumab, tabalumab or other biologic agents directly targeting Interleukin 17 (IL-17) and/or B cells (e.g., rituximab, belimumab, etc.) are excluded